|
|
|
 |
|
 |
 |
|||
Company News
|
eFFECTOR Therapeutics Raises $45 Million in Series A Financing
Company to Focus on Small Molecule Selective Translation Regulators for Cancer
San Diego - CA, 20 May 2013
-
top
GenSight Biologics Raises €32m in a Series A Financing for Ophthalmic Gene Therapy
Paris, France, 08 April 2013
top
Avedro Completes $43 Million Series D Financing
WALTHAM, Mass, 05 March 2013
top
Gynesonics Completes $21 Million Series D Financing
Financing Validates the Attractiveness of VizAblate®
REDWOOD CITY, Calif, 22 February 2013
top
Roche and Chiasma announce collaboration to develop and commercialize Chiasma’s Octreolin® for acromegaly and neuroendocrine tumors
Jerusalem, Israel, 18 February 2013
top
U.S. FDA Approval of Aorfix™
London, UK,, 15 February 2013
top
Avillion LLP receives initial funding from Abingworth and Clarus
London, UK, 28 January 2013
top
Labcyte Inc. Closes $5.3 Million Financing
Sunnyvale, CA, 08 January 2013
top
|
Archive:
|
|||||||||||||||||||||||||||||||||||||||||||||
Andrew Kay, President and CEO of Algeta
Abingworth set a highly professional tone from the beginning. The due diligence was detailed and incisive and this attention to detail continued as Algeta became one of their portfolio companies. It is Abingworth's support capability that really distinguishes them. This includes market analytics, finance, commercial intelligence, and search expertise for executive managers and board members. They have extensive networks with big companies, biotechs and banks that provides invaluable introductions and contacts. What is quite remarkable is that despite being one of many portfolio companies, everyone across the Abingworth organisation seems to know who you are and they are responsive and enthusiastic about thinking of ways to help, identifying opportunities, issues and solutions.